GeneDx Holdings (GeneDx Holdings) Interest Expense : $-2.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. GeneDx Holdings's interest expense for the three months ended in Mar. 2024 was $ -0.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. GeneDx Holdings's Operating Income for the three months ended in Mar. 2024 was $ -13.7 Mil. GeneDx Holdings's Interest Expense for the three months ended in Mar. 2024 was $ -0.6 Mil. GeneDx Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

GeneDx Holdings Interest Expense Historical Data

The historical data trend for GeneDx Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings Interest Expense Chart

GeneDx Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.78

-2.47

-2.84

-3.21

GeneDx Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial											-0.04	-0.63	-	-0.98	-0.60

GeneDx Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.2 Mil.

GeneDx Holdings (NAS:WGS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

GeneDx Holdings's Interest Expense for the three months ended in Mar. 2024 was $-0.6 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-13.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $114.3 Mil.

GeneDx Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GeneDx Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

GeneDx Holdings (GeneDx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902

Website

https://www.genedx.com

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.

Executives

Kareem Saad	officer: Chief Business Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland	director, officer: Chief Executive Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley	officer: Chief Financial Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister	director, 10 percent owner	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White	officer: Chief People Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp	director, 10 percent owner	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp	director, 10 percent owner	667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137